Pharma calls for Australian version of early access, adaptive licensing schemes
This article was originally published in SRA
Australia's Therapeutic Goods Administration should take steps to align its drug approval processes with those of the major overseas regulators and launch new product registration pathways that would allow patients to have earlier access to medicines in areas of high unmet needs or to drugs representing significant medical innovation1.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.